how many of the reviewers performed the quality assessment.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction.
The data extracted from the RCTs included: author, study design, patient numbers, age, motor types, severity at baseline, follow-up, drop-outs, loss to follow-up, intervention, outcome measures, complications/side-effects, and the main result. Additional data extracted from the non-randomised studies were the study aim, objective outcome, and the number of groups. Data required to assess methodological quality were also extracted from the RCTs.
Methods of synthesis
How were the studies combined? A meta-analysis using a fixed-effect model was used to calculate the pooled weighted risk difference, along with 95% confidence intervals (CIs), for the noncontinuous outcomes reported in the RCTs. Summary tables of the nonrandomised studies were constructed, and their findings were discussed separately.
How were differences between studies investigated?
A chi-squared statistical test for heterogeneity was used in the meta-analyses. The only means of evaluating differences between the non-randomised studies was to examine the tables.
Results of the review
Ten RCTs (n=407) and 7 prospective non-randomised studies (n=193) were included.
The methodological quality of the included RCTs was moderate to high (at least 7 points out of a possible 11); 9 trials had concealed allocation.
The pooled risk difference for BTX-A versus placebo was 0.25 (95% CI: 0.13, 0.37); this was based on 4 RCTs (n=204) that used the physicians rating scale as the primary outcome measure. The chi-squared test showed no statistically-significant heterogeneity (chi-squared 3.83, d.f.=3, P=0.28). Similarly, the pooled risk difference for BTX-A versus casting was 0.23 (95% CI: -0.06, 0.53); this was based on 2 RCTs (n=38) with no statistically-significant heterogeneity (chi-squared 0.24, d.f.=1, P=0.62). Pooling all 6 trials showed a risk difference of 0.24 (95% CI: 0.13, 0.36) and no statistically-significant heterogeneity. For this analysis, success was defined a priori as an increase of at least two points from the baseline composite physician rating scale score. The trials assessed the outcome at 6 to 16 weeks' follow-up.
Authors' conclusions
The findings from the meta-analysis represent moderate treatment effects that are dose-dependent.
CRD commentary
This article reported a systematic review within a broader and less focused evidence summary. This abstract summarised only the results of the systematic review question. Readers interested in the categorisation of all identified papers (regardless of the inclusion criteria for the systematic review) according to the levels of evidence and the ICIDH-2 model, should read the original article.
The systematic review addressed a clear question in terms of the participants, intervention, comparators and study design, but not in terms of the outcome measures. A variety of appropriate sources were searched to identify trials. However, publication bias is a real possibility; publication in a peer-reviewed journal is not a guarantee of methodological quality, and is a questionable limitation to impose on a review in which the authors themselves critically appraise the primary studies. It is unclear whether or not language restrictions were imposed. Details of the
